Erasing iatrogenic neoantigens from in vivo CRISPR screens Editorial
| Authors: | Yi, F.; Klebanoff, C. A. |
| Title: | Erasing iatrogenic neoantigens from in vivo CRISPR screens |
| Abstract: | In vivo genetic screens using CRISPR-Cas9 are a powerful tool to resolve the molecular determinants of response and resistance to cancer immunotherapies; however, vector immunogenicity can introduce artifact. In this issue of Immunity, Dubrot et al. report a strategy to “erase” vector-associated neoantigens, enabling a more physiologic assessment of tumor-immune cell interactions in immunocompetent hosts. © 2021 Elsevier Inc. In vivo genetic screens using CRISPR-Cas9 are a powerful tool to resolve the molecular determinants of response and resistance to cancer immunotherapies; however, vector immunogenicity can introduce artifact. In this issue of Immunity, Dubrot et al. report a strategy to “erase” vector-associated neoantigens, enabling a more physiologic assessment of tumor-immune cell interactions in immunocompetent hosts. © 2021 Elsevier Inc. |
| Keywords: | cancer immunotherapy; in vivo study; immunogenicity; artifact; cell interaction; immunocompetent cell; article; crispr-cas9 system |
| Journal Title: | Immunity |
| Volume: | 54 |
| Issue: | 3 |
| ISSN: | 1074-7613 |
| Publisher: | Cell Press |
| Date Published: | 2021-03-09 |
| Start Page: | 406 |
| End Page: | 408 |
| Language: | English |
| DOI: | 10.1016/j.immuni.2021.02.017 |
| PUBMED: | 33691131 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 April 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work